Efficacy and Safety of Ertugliflozin in Patients with Overweight and Obesity with Type 2 Diabetes Mellitus

Long-term efficacy and safety of ertugliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin monotherapy: 104-week VERTIS MET trial

(2019) Silvina Gallo et al.   DIABETES OBESITY & METABOLISM

Emerging Role of SGLT-2 Inhibitors for the Treatment of Obesity

(2019) Maria J. Pereira et al.   DRUGS

Results of VERTIS SU extension study: safety and efficacy of ertugliflozin treatment over 104 weeks compared to glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin

(2019) Priscilla Hollander et al.   CURRENT MEDICAL RESEARCH AND OPINION

Efficacy of ertugliflozin in monotherapy or combination therapy in patients with type 2 diabetes: A pooled analysis of placebo-controlled studies

(2019) Jie Liu et al.   Diabetes & Vascular Disease Research

Ertugliflozin plus sitagliptin versus either individual agent over 52 weeks in patients with type 2 diabetes mellitus inadequately controlled with metformin: The VERTIS FACTORIAL randomized trial

(2018) Richard E. Pratley et al.   DIABETES OBESITY & METABOLISM

Pharmacotherapy for obesity in individuals with type 2 diabetes

(2018) Tariq Chukir et al.   EXPERT OPINION ON PHARMACOTHERAPY

Ertugliflozin and Sitagliptin Co-initiation in Patients with Type 2 Diabetes: The VERTIS SITA Randomized Study

(2018) Sam Miller et al.   Diabetes Therapy

Ertugliflozin and Sitagliptin Co-initiation in Patients with Type 2 Diabetes: The VERTIS SITA Randomized Study

(2018) Sam Miller et al.   Diabetes Therapy

Design and baseline characteristics of the eValuation of ERTugliflozin effIcacy and safety CardioVascular outcomes trial (VERTIS-CV)

(2018) Christopher P. Cannon et al.   AMERICAN HEART JOURNAL

Weight loss associated with sodium-glucose cotransporter-2 inhibition: a review of evidence and underlying mechanisms

(2018) P. C. Lee et al.   Obesity Reviews

8. Obesity Management for the Treatment of Type 2 Diabetes: Standards of Medical Care in Diabetes—2019

(2018)   DIABETES CARE

Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

(2018) Melanie J. Davies et al.   DIABETES CARE

The Association Between the Dosage of SGLT2 Inhibitor and Weight Reduction in Type 2 Diabetes Patients: A Meta-Analysis

(2017) Xiaoling Cai et al.   Obesity

Ertugliflozin Compared with Glimepiride in Patients with Type 2 Diabetes Mellitus Inadequately Controlled on Metformin: The VERTIS SU Randomized Study

(2017) Priscilla Hollander et al.   Diabetes Therapy

Ertugliflozin in Patients with Stage 3 Chronic Kidney Disease and Type 2 Diabetes Mellitus: The VERTIS RENAL Randomized Study

(2017) George Grunberger et al.   Diabetes Therapy

Ertugliflozin Compared with Glimepiride in Patients with Type 2 Diabetes Mellitus Inadequately Controlled on Metformin: The VERTIS SU Randomized Study

(2017) Priscilla Hollander et al.   Diabetes Therapy

Ertugliflozin in Patients with Stage 3 Chronic Kidney Disease and Type 2 Diabetes Mellitus: The VERTIS RENAL Randomized Study

(2017) George Grunberger et al.   Diabetes Therapy

Effects of Moderate and Subsequent Progressive Weight Loss on Metabolic Function and Adipose Tissue Biology in Humans with Obesity

(2016) Faidon Magkos et al.   Cell Metabolism

Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus

(2016) Hiddo J.L. Heerspink et al.   CIRCULATION

Efficacy and safety of sodium-glucose co-transporter-2 inhibitors in type 2 diabetes mellitus: systematic review and network meta-analysis

(2016) F. Zaccardi et al.   DIABETES OBESITY & METABOLISM

Efficacy and safety of canagliflozin in patients with type 2 diabetes

(2016) Wei Xiong et al.   MEDICINE

Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION-8): a 28 week, multicentre, double-blind, phase 3, randomised controlled trial

(2016) Juan P Frías et al.   Lancet Diabetes & Endocrinology

Baseline Body Mass Index and the Efficacy of Hypoglycemic Treatment in Type 2 Diabetes: A Meta-Analysis

(2016) Xiaoling Cai et al.   PLoS One

The Efficacy and Effectiveness in HBA1C-Lowering is Dependent on Baseline Body Mass Index (BMI) for Sitagliptin but not Canagliflozin in the Treatment of Type 2 Diabetes Mellitus (T2DM)

(2014) J. Diels et al.   VALUE IN HEALTH

Blood Pressure Targets in Subjects With Type 2 Diabetes Mellitus/Impaired Fasting Glucose

(2011) Sripal Bangalore et al.   CIRCULATION

Predictors of response to dipeptidyl peptidase-4 inhibitors: evidence from randomized clinical trials

(2011) Matteo Monami et al.   DIABETES-METABOLISM RESEARCH AND REVIEWS

Preclinical Species and Human Disposition of PF-04971729, a Selective Inhibitor of the Sodium-Dependent Glucose Cotransporter 2 and Clinical Candidate for the Treatment of Type 2 Diabetes Mellitus

(2011) A. S. Kalgutkar et al.   DRUG METABOLISM AND DISPOSITION

The efficacy of lowering glycated haemoglobin with a gliclazide modified release-based intensive glucose lowering regimen in the ADVANCE trial

(2010) S. Zoungas et al.   DIABETES RESEARCH AND CLINICAL PRACTICE

Effect of Noninsulin Antidiabetic Drugs Added to Metformin Therapy on Glycemic Control, Weight Gain, and Hypoglycemia in Type 2 Diabetes

(2010) Olivia J. Phung   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 Diabetes

(2008)   NEW ENGLAND JOURNAL OF MEDICINE